Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

PTC Therapeutics Inc (NASDAQ:PTCT)

8.64
Delayed Data
As of Mar 22
 +0.27 / +3.23%
Today’s Change
4.03
Today|||52-Week Range
16.50
-20.81%
Year-to-Date
Frontrunning: March 17
Mar 17 / Investing Channel - Paid Partner Content
Biotech Premarket Movers: Seres, PTC, Inovio
Mar 16 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close8.37
Today’s open8.36
Day’s range8.12 - 8.67
Volume1,636,195
Average volume (3 months)1,397,880
Market cap$298.6M
Dividend yield--
Data as of 03/22/2017

Growth & Valuation

Earnings growth (last year)+17.75%
Earnings growth (this year)--
Earnings growth (next 5 years)--
Revenue growth (last year)+124.95%
P/E ratioNM
Price/Sales4.49
Price/Book2.47

Competitors

 Today’s
change
Today’s
% change
TTPHTetraphase Pharmaceu...-0.13-1.64%
CMRXChimerix Inc+0.22+3.67%
ADXSAdvaxis Inc-0.12-1.53%
MTNBMatinas BioPharma Ho...+0.05+1.56%
Data as of 03/22/2017

Financials

Last reporting dateMarch 16, 2017
EPS forecast (this quarter)-$1.04
Annual revenue (last year)$82.7M
Annual profit (last year)-$142.1M
Net profit margin-171.83%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Class I Director
Stuart W. Peltz
Executive VP-Research, Operations &
Technology
Neil Gregory Almstead
Corporate headquarters
South Plainfield, New Jersey

Forecasts


Search for Jobs